Abstract

Type II diabetes Mellitus is one of the common diseases worldwide and often recognized as life style disease. The major symptom of this disease is an increase in blood glucose level resulting in polydypsia, polyuria and polyphagia. Molecular modeling was used to design the drug molecules. Docking results showed imidazolidine derivatives have good interaction with the DPP IV receptors. The compound IMA4 showed good orientation and score. This novel compound represents potential scaffold for the design of clinically useful DPP IV inhibitors.

Keywords: Docking, DPP IV, Imidazolidine, Molecular modeling, Dipeptidyl Peptidase, oligopeptides, neuropeptides, insulinotropic action, cytokines, post-meal glycemic